OCHRE BIO
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
OCHRE BIO
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2019-09-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.ochre-bio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
9.75 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome Domain Not Resolving
Similar Organizations
Allakos
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
D2G Oncology
D2G Oncology is a biotechnology company that specializes in relating drugs to genotypes to transform precision cancer therapeutics.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Bioverge
Bioverge investment in Series A - Ochre Bio
Milad Alucozai
Milad Alucozai investment in Series A - Ochre Bio
FAST — by GETTYLAB
FAST — by GETTYLAB investment in Series A - Ochre Bio
LifeLink Ventures
LifeLink Ventures investment in Series A - Ochre Bio
Acequia Capital (AceCap)
Acequia Capital (AceCap) investment in Series A - Ochre Bio
Hoxton Ventures
Hoxton Ventures investment in Seed Round - Ochre Bio
Hermes-Epitek
Hermes-Epitek investment in Seed Round - Ochre Bio
Apollo Health Ventures
Apollo Health Ventures investment in Seed Round - Ochre Bio
BACKED VC
BACKED VC investment in Seed Round - Ochre Bio
Khosla Ventures
Khosla Ventures investment in Seed Round - Ochre Bio
Official Site Inspections
http://www.ochre-bio.com Semrush global rank: 6.66 M Semrush visits lastest month: 892
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ochre Bio"
Ochre Bio - Crunchbase Company Profile & Funding
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly …See details»
Oxford biotech raises funds to make RNA treatments …
Oct 10, 2022 Ochre Bio has already analysed data from more than 1,000 diseased livers in collaboration with Oxford university in an approach called deep phenotyping, which combines imaging, genetic and ...See details»
Member profile: Ochre Bio Ltd | BIA
Ochre Bio develops genomic medicines that rejuvenate transplanted livers, ultimately with the goal of applying these therapies to treat fatty liver disease (NASH/NAFL) and other metabolic …See details»
UK biotech signs $1bn deal to develop liver disease …
Apr 22, 2024 Jack O’Meara, chief executive of Ochre Bio, told the Financial Times: “There still remains a huge unmet need there and we hope this partnership with Boehringer will be able to develop ...See details»
EIT Health-supported start-up Ochre Bio signs $1BN+ deal with ...
May 7, 2024 Oxford-based Ochre Bio has closed a deal to the value of $1BN+ with European drugmaker Boehringer Ingelheim. Ochre Bio is a biotechnology company developing RNA …See details»
Ochre Bio Announces Partnership with Boehringer …
Apr 22, 2024 About Ochre Bio. Ochre Bio is a biotechnology company developing novel RNA medicines for under-treated chronic liver diseases. Its proprietary discovery platform combines machine learning and big human …See details»
Ochre Bio announces partnership with Boehringer Ingelheim to …
OXFORD, England, April 22, 2024--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim …See details»
Ochre Bio and Boehringer enter CLD regenerative therapy deal
Apr 23, 2024 Ochre Bio has entered a strategic collaboration with Boehringer Ingelheim to discover and develop new regenerative treatments for treating chronic liver diseases (CLDs). …See details»
RNA Therapies in Liver Disease: Insights from Ochre …
Jan 24, 2024 In this interview, we speak with Jack O'Meara, co-founder and CEO of Ochre Bio, a pioneering force in liver disease treatment. O'Meara shares insights into Ochre Bio's innovative RNA therapies ...See details»
Irish-founded Ochre Bio raises $30m to develop liver …
Oct 19, 2022 Ochre Bio has raised $30m in a Series A funding round to find new treatments for chronic liver disease. The Oxford-based start-up was founded by Quin Wills and Athlone native Jack O’Meara in 2019.See details»
Ochre Bio raises $30 million for RNA-based liver disease therapies
Oct 15, 2022 Ochre Bio has raised $30 million in series A funding to develop RNA therapies for chronic liver diseases. The UK start-up creates potential RNA therapies to reprogram the liver …See details»
Ochre Bio Raises $30M Series A Financing for the Development of …
Oct 10, 2022 Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of deep phenotyping, precision RNA medicine, and testing in …See details»
Founder Spotlight #5: Jack O’Meara @ Ochre Bio - Medium
Jun 16, 2020 Jack O’Meara is Co-Founder & CEO @ Ochre Bio, a genomics-based drug discovery company developing siRNA therapies to rejuvenate transplanted livers. Jack is a …See details»
Boehringer Ingelheim, Ochre Bio Launch Up-to-$1B+ Liver Disease …
Apr 22, 2024 The collaboration with Ochre Bio is Boehringer’s second billion-dollar-plus partnership announced this year focused on liver disease. In January, Boehringer joined …See details»
Ochre Bio announces partnership with Boehringer Ingelheim to
Apr 22, 2024 Ochre Bio, a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and …See details»
Ochre Bio: fully human, super speedy liver drug development
Feb 8, 2024 Liver disease company Ochre has a three-part system for validating siRNA therapeutic targets that relies entirely on human cells and tissues, sidestepping the problems …See details»
GSK Enters Into a Multi-Year Data Licence Agreement With Ochre …
Jun 12, 2024 OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence …See details»
Ochre Bio Closes $9.6M Seed Financing Led by Khosla Ventures
Jun 16, 2021 Ochre Bio has built a deep phenotyping platform to identify novel liver targets, validated directly in discarded human livers kept alive on machines. June 16, 2021 08:00 AM …See details»
Boehringer signs $1.3B MASH collab with RNA biotech Ochre
Apr 22, 2024 The German drugmaker is paying British biotech Ochre Bio $35 million in upfront and near-term research-based milestone payments to investigate “multiple targets” for chronic …See details»